Vaccines Against Multiple System Atrophy (MSA)
Multiple system atrophy is one of the neurodegenerative diseases. Although rare, it has a significant impact on the patient's quality of life, dignity, and health. Related vaccines are an effective strategy for dealing with this problem. Creative Biolabs has more than 10 years of experience in the field of vaccines, especially in the study of vaccines for neurodegenerative diseases such as Parkinson's and Alzheimer's. We have helped our clients around the world complete their research tasks perfectly.
Multiple System Atrophy (MSA) and Pathogenesis
Multiple system atrophy (MSA), also known as Shy-Drager syndrome, is a relatively rare neurodegenerative disease (also known as synucleinopathies). Progressive degeneration of neurons in some parts of the brain leads to dysfunction of the nervous system, which in turn leads to the development of the disease. Some of the symptoms of MSA are similar to those of Parkinson's disease, but MSA patients have little response to dopamine. There are no clear conclusions about the etiology of MSA. Some studies have shown that like other neurodegenerative diseases such as Parkinson's, the accumulation of abnormal alpha-synuclein protein may be the culprit. For the heritability of the disease, a study in some patients indicated that the development of MSA may have a correlation with the deletion of genes in specific regions. While it is worth noting that this result from Japanese patients cannot be replicated in MSA patients in the United States, scientists suspect that the disease may be heterogeneous in different genetic backgrounds. Cell loss in the damaged region of the central nervous system, proliferation of astrocytes are the main pathological manifestation of MSA. The inclusion bodies, mainly composed of alpha-synuclein, are also called Papp-Lantos bodies, and their presence in the areas of brain responsible for movement, balance, and automatic control is a clear pathological feature of MSA.
Development of Vaccines against MSA
There is currently no cure for MSA, and the current treatment options are mainly supportive. Based on the recognition that excessive aberrant a-syn accumulation leads to neurodegenerative diseases, scientists set the target for developing MSA vaccines to a-syn, and most of designs for the related vaccines are based on this. Therefore, many vaccines targeting a-syn-specific antibodies have been developed. These include a-syn synthetic peptide or protein vaccines, DNA vaccines, and dendritic cell vaccines. As a pioneer in the implementation of this strategy, a full-length a-syn vaccine aimed at producing antibodies capable of binding a-syn with high affinity has shown promise in that mice overexpressing human a-syn have elicited corresponding antibodies after immunization with the vaccine, and the level of abnormal a-syn in the neurons of the model mice has decreased, which in turn alleviate the degree of neurodegeneration. More importantly, in this study, detrimental neuroinflammatory responses were not detected and all of these results demonstrate the feasibility and potential of this strategy. Although these results are very encouraging, there are still a lot of risks if this full-length vaccine enters clinical trials, because as a self-protein, a-syn may trigger an a-syn-specific autoimmune response. As such, subsequent vaccine development aims to achieve the same goals by using shorter peptides derived from a-syn. As another vaccine strategy, nucleic acid vaccines have also obtained promising results in preclinical studies on AD, PD, and the like. Dendritic cell vaccines have received more and more attention and development in cancer research in recent years. Dendritic cells not only play a key role in stimulating immune responses, but they are also found to be less toxic in clinical trials. Mice that immunized with a DC vaccine designed for PD were found to be able to elicit specific anti-a-syn antibodies, and compared to the control group, the neuroinflammation markers in the brain of the immunized mice have also decreased.
Vaccination is a potential approach to solving neurodegenerative diseases because it is not only widely applicable, possessing the ability of avoiding cumbersome administration, but also inexpensive to produce. Creative Biolabs aims to create a healthier and happier human society and has been at the forefront of disease prevention for decades. We continue to absorb the best R&D talents and continuously establish and improve more mature and advanced R&D platforms. As a result, we have become the benchmark in the vaccine field and have been recognized and praised by colleagues all over the world. If you have any needs for vaccine research, please feel free to contact us!
All of our products can only be used for research purposes. These vaccine ingredients CANNOT be used directly on humans or animals.
